BMS Receives FDA Breakthrough Designation for Daclatasvir Dual Regimen

Bristol-Myers Squibb says the FDA has designated its investigational combination of daclatasvir and asunaprevir a breakthrough therapy to treat certain hepatitis C patients.
MarketWatch